Dr. Ahmed Elkhanany
Claim this profileUniversity of Alabama at Birmingham Cancer Center
Studies Breast Cancer
Studies Breast cancer
10 reported clinical trials
24 drugs studied
Area of expertise
1Breast Cancer
Stage IV
ER positive
Stage III
2Breast Cancer
Stage IV
HER2 negative
Stage III
Affiliated Hospitals
Clinical Trials Ahmed Elkhanany is currently running
Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib
for Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
More about Ahmed Elkhanany
Clinical Trial Related1 year of experience running clinical trials · Led 10 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Ahmed Elkhanany has experience with
- Avelumab
- Trastuzumab
- Abemaciclib
- Fulvestrant
- Paclitaxel
- Estradiol
Breakdown of trials Ahmed Elkhanany has run
Breast Cancer
Breast cancer
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ahmed Elkhanany specialize in?
Ahmed Elkhanany focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are ER positive.
Is Ahmed Elkhanany currently recruiting for clinical trials?
Yes, Ahmed Elkhanany is currently recruiting for 5 clinical trials in Birmingham Alabama. If you're interested in participating, you should apply.
Are there any treatments that Ahmed Elkhanany has studied deeply?
Yes, Ahmed Elkhanany has studied treatments such as Avelumab, Trastuzumab, Abemaciclib.
What is the best way to schedule an appointment with Ahmed Elkhanany?
Apply for one of the trials that Ahmed Elkhanany is conducting.
What is the office address of Ahmed Elkhanany?
The office of Ahmed Elkhanany is located at: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama 35233 United States. This is the address for their practice at the University of Alabama at Birmingham Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.